Pulmatrix, Inc. (NasdaqCM:PULM) has retained MTS Health Partners, L.P. (MTS) as its financial advisor to support the company's Board of Directors and management team to review and evaluate strategic alternatives intended to maximize long-term value for all stockholders.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -3.03% | +0.01% | +3.23% |
May. 17 | Pulmatrix Files Up to $95 Million Mixed Shelf | MT |
May. 15 | Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine | CI |
1st Jan change | Capi. | |
---|---|---|
+3.23% | 7.23M | |
+10.67% | 115B | |
+12.61% | 106B | |
-4.26% | 24.69B | |
-1.92% | 21.97B | |
-5.57% | 19.27B | |
-11.45% | 17.56B | |
-39.36% | 17.32B | |
+5.99% | 14.03B | |
+32.91% | 12.13B |
- Stock Market
- Equities
- PULM Stock
- News Pulmatrix, Inc.
- Pulmatrix Explores Strategic Alternatives